Neuberger Berman Group
SAGE

Neuberger Berman Group’s Sage Therapeutics SAGE Stock Holding History

Neuberger Berman Group’s Portfolio SAGE Stock Details SAGE Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2018
Q2 		– Sell
-3,459
Closed -$557K – 1748
2018
Q1 		$557K Buy
3,459
+459
+15% +$77.9K ﹤0.01% 1332
2017
Q4 		$494K Buy
+3,000
New +$291K ﹤0.01% 1406
2017
Q2 		– Sell
-3,000
Closed -$213K – 1634
2017
Q1 		$213K Buy
+3,000
New +$176K ﹤0.01% 1520
2015
Q1 		– Sell
-14,500
Closed -$530K – 1649
2014
Q4 		$530K Buy
+14,500
New +$540K ﹤0.01% 1339

Other funds holding SAGE

T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $580B AUM 38.23% 1-Year Est. Return
O
OppenheimerFunds New York $80.4B AUM 15.1% 1-Year Est. Return
Bank of New York Mellon
Bank of New York Mellon New York $609B AUM 40.19% 1-Year Est. Return
BB
BB Biotech Schaffhausen, Switzerland $3.98B AUM 15.47% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.81T AUM 41.13% 1-Year Est. Return

Neuberger Berman Group's SAGE Position: Q2 2018 in Review

Neuberger Berman Group sold out of Sage Therapeutics (SAGE) in Q2 2018, closing a stake of 3,459 shares — an estimated $557K sold.

Neuberger Berman Group first reported a position in SAGE in Q4 2014 and held it in 4 quarters. The position peaked at $557K in Q1 2018. 269 funds tracked by Wall St. Rank hold SAGE as of Q2 2018.

  • Neuberger Berman Group reported no remaining Sage Therapeutics position as of Q2 2018 after selling out during the quarter.
  • Neuberger Berman Group sold 3,459 Sage Therapeutics shares in Q2 2018, an estimated $557K.
  • Neuberger Berman Group first reported a position in Sage Therapeutics in Q4 2014 and held it in 4 quarters.
  • Neuberger Berman Group's Sage Therapeutics position peaked at $557K in Q1 2018.
  • 269 funds tracked by Wall St. Rank held Sage Therapeutics as of Q2 2018.

Based on Neuberger Berman Group's 13F filing for Q2 2018, filed 13 Aug 2018.